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tion­of­ZCJ14­ in­ rat­plasma.­Furthermore,­ the­method­was­
applied­to­investigate­the­pharmacokinetic­characteristics­of­
ZCJ14.­ Chromatographic­ separation­ of­ ZCJ14­ and­ internal­
standard­(IS)­[1-phenyl-3-(4-((3-(trifluoromethyl)phenyl)ami-
no)quinazolin-6-yl)urea]­was­accomplished­by­gradient­elu-
tion­using­ the­Kromasil­C18­ column.­The­ selected­ reaction­
monitoring­transitions­were­performed­at­m/z­507.24→436.18­
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Table I. Gradient elution program
Time­(min) 0 1 2 8 9 10
Mobile­phase
A 50 50 2 2 50 50
B 50 50 98 98 50 50
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lyte­ (expressed­as­RSD,­%).­The­acceptance­ standard­ should­be­within­85.0–115.0­%­of­
nominal­ concentration­ and­ 15.0­%­RSD­ for­ accuracy­ and­precision,­ resp.,­whereas­ for­
LLOQ­QC­(10­ng­mL–1),­the­accuracy­and­precision­should­be­within­±­20.0­%.
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Specificity and selectivity. –­Representative­chromatograms­of­blank­rat­plasma,­blank­
rat­plasma­spiked­with­IS­and­ZCJ14­(LLOQ,­10­ng­mL–1),­a­plasma­sample­harvested­at­
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Matrix effect and extraction recovery. –­Table­IV­summarizes­the­matrix­effect­and­extrac-
tion­recovery­of­ZCJ14­and­IS.­The­matrix­effect­for­ZCJ14­was­93.6­±­4.9,­109.9­±­7.2­and­87.3­±­
5.3­%­at­concentration­levels­of­20,­100­and­800­ng­mL–1,­resp.­The­matrix­effect­for­IS­(200­ng­















ZCJ14 4.77 0.26 6.22 – 1.28 5919
IS 6.00 0.39 8.15 4.11 1.17 14994






















10.0 9.9­±­1.2 12.1 99.0 9.8­±­1.4 14.3 98.0
20.0 17.5­±­0.8 4.6 87.5 18.7­±­2.0 10.7 93.5
100.0 94.5­±­7.3 7.7 94.5 95.8­±­5.8 6.1 95.8
800.0 743.5­±­81.6 11.0 92.9 725.2­±­49.4 6.8 90.7
a Mean­±­SD,­n­=­5.
423
S.-J. Zuo et al.: Quantitative analysis and pharmacokinetic study of a novel diarylurea EGFR inhibitor (ZCJ14) in rat plasma using a 

















S.-J. Zuo et al.: Quantitative analysis and pharmacokinetic study of a novel diarylurea EGFR inhibitor (ZCJ14) in rat plasma using a 
















20 93.6­±­4.9 5.2 92.1­±­11.7 12.7
100 109.9­±­7.2 6.6 101.0­±­2.9 2.9
800 87.3­±­5.3 6.1 88.4­±­6.2 7.0
IS 200 87.8­±­5.2 5.9 104.5­±­9.7 9.3
a Mean­±­SD,­n­=­5.






20.0 18.6­±­2.2 93.0 11.9
100.0 106.2­±­9.1 106.2 8.6
800.0 899.5­±­126.2 112.4 14.0
15­days,­–20­°C
20.0 19.9­±­2.7 99.5 13.8
100.0 112.9­±­8.9 112.9 7.8
800.0 814.6­±­55.1 101.8 6.8
Three­freeze-thaw­
cycles
20.0 19.6­±­2.7 98.0 13.9
100.0 109.8­±­4.0 109.8 3.7
800.0 806.3­±­106.4 100.8 13.2
a Mean­±­SD,­n­=­5.





MRT0-inf_obs (h) 22.2­±­2.1 5.3­±­1.5
t1/2­(h) 7.7­±­2.9 5.9­±­1.4
Tmax (h) 18.0­±­1.3 –
Cmax­(ng­mL–1) 350.4­±­63.7 –
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resp.­ As­ some­ of­ the­ plasma­
­samples­ exceeded­ the­ standard­
curve­ range,­ proper­ dilution­ of­
these­ samples­ was­ carried­ out­
with­blank­rat­plasma­using­the­


















ed­ to­ the­ solubility­ of­ ZCJ14.­
Compound­ ZCJ14­ is­ lipophilic.­
After­ peroral­ administration,­
only­one­portion­of­ZCJ14­was­ab-




slowly,­which­ led­ to­ the­ forma-
tion­of­a­second­peak­after­a­long­
period­of­time.­Secondly,­gastric­
motility­ may­ be­ affected­ by­
ZCJ14.­This­may­explain­the­for-
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